Amgen Inc

AMGN remains in a Stage 2 advancing regime with a clear bullish medium-term trend confirmed by successive higher highs and lows. The recent pullback into the rising 9/20 EMA zone on low volume offers a favorable entry point, supported by decompressed RSI and stable forward P/E. Short-term conditions favor buying now at the confluence of EMAs, with price holding above the key moving averages. Key risks include a deeper pullback breaching the 20 EMA or failure to hold support, which would challenge the bullish bias.

• ↑Revenue rose 9% YoY to $8.1B, driven by 14% volume growth
• ↑Non-GAAP operating margin of 45% highlights strong profitability
• ↓Negative growth trends and severe revision risks signal outlook deterioration